Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 22;13:1040665. doi: 10.3389/fonc.2023.1040665

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Pettersen, Øy, Egeland, Juell, Engebråten, Mælandsmo and Prasmickaite

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Sensitivity of MAS98.12/MAS98.12PR PDXs and the respective PDXCs to capecitabine. (A) Relative tumor volume (normalized to the volume at the day when the treatment was started) of non-treated and capecitabine-treated (540 mg/kg, 5x/week) MAS98.12 and MAS98.12PR PDX; average ± SEM (n indicated in the legend). (B, C) PDXCs in Matrigel with/without capecitabine treatment for one week followed by calcein/PI staining (representative pictures in (B)) to quantify the proportion of viable cells among all cells (C). (B) Representative fluorescent pictures; scale bar, 200 μm. (C) A proportion of viable cells in the treated cultures presented as a percentage of the respective untreated controls; average ± SEM (n=3); * and **, p < 0.05 by unpaired and paired t-test, respectively.